
Henlius and Sandoz partner on up to 10 biosimilar products, targeting $100.5M revenue in 2026
Shanghai Henlius Biotech has formed a strategic collaboration with Sandoz to develop and commercialize up to 10 monoclonal antibody and antibody-drug conjugate biosimilars globally, excluding China. The partnership builds on their 2025 oncology biosi...


